As a biosimilar to Actemra, tocilizumab-anoh in both IV and SC formulation is approved to treat rheumatoid arthritis, pJIA, sJIA, COVID-19, and giant cell arteritis. The FDA recently approved ...

Department of Thoracic Oncology, Jiangxi Cancer Hospital & Institute, Jiangxi Clinical Research Center for Cancer, The second Affiliated Hospital of Nanchang Medical College, Nanchang, China ...

The FDA’s decision is based on a comprehensive data package and the totality of evidence, including the results from a phase III study demonstrating biosimilarity between AVTOZMA and reference ...

Cipla Q3 results review: The shares of the third largest pharmaceutical firm Cipla rose 2.44 per cent at Rs 1,454.20 a piece on the BSE intraday after the company delivered a solid quarterly earnings ...

Cipla has been helping extend the reach of affordable life-saving HIV/AIDS medications since 2001. The company supplies antiretroviral (ARV) medicines to 64 countries by mostly participating in the ...

Shares of drugmaker Cipla Ltd. surged to the day's high, gaining as much as 4% after the company's December quarter results. The results were a beat across parameters.

HYDERABAD/BENGALURU (Reuters) -Cipla, one of India's largest drugmakers by sales, reported a bigger-than-expected third-quarter profit on Tuesday helped by strong domestic demand, and said the U.S ...

Drug major Cipla on Tuesday reported a 49% jump in its December quarter consolidated net profit at Rs 1,571 crore as compared to Rs 1,056 crore reported in the year-ago period. The profit after tax ...

Cipla Ltd.'s consolidated net profit rose 49% year-on-year in the third quarter of the current financial year, beating analysts' estimates by a substantial margin. The drugmaker posted a consolidated ...

After topping the Street's expectations with its Q3 earnings, Cipla announced plans to launch two key drugs in FY26—the respiratory drug Advair and the oncology drug Abraxane. Umang Vohra ...

Pharmaceutical giant Cipla on January 28 reported a consolidated net profit of Rs 1,571 crore for the quarter ended on December 31. This marks a 49 percent rise from the Rs 1,056 crore net profit ...

Shares traded at ₹358.05 on the NSE, down 2.09%. Cipla Ltd recorded its consolidated net profit for the quarter ended December 2024 at ₹1,574.59 crore as against ₹1,068.41 crore in the ...